ScreenerHero

EVMN Evommune, Inc.

NYSE · US · Healthcare · Biotechnology · evommune.com
6.220USD-5.90%Mkt Cap: 225.74M $P/E: —

Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap225.74M USD
Enterprise Value47.73M USD
Revenue (TTM)10.00M USD
Gross Profit10.00M USD
Net Income (TTM)-68.87M USD
Revenue/Share0.44 USD
Last Price6.220 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees48
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.87
PEG—
EV/EBITDA-0.48
EV/Revenue4.77
P/S23.99
P/B0.86
EPS (TTM)-3.75
EPS (Forward)-3.54
52W Range
6.0801% of range33.20
52W High33.20 USD
52W Low6.080 USD
Profitability
Gross Margin100.00%
Oper. Margin-1018.94%
EBITDA Margin0.00%
Profit Margin-529.77%
ROE-33.50%
ROA-30.62%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-76.44M USD
CapEx (TTM)235.00K USD
FCF Margin-391.28%
FCF Yield-17.33%
Net Debt-192.16M USD
Net Debt/EBITDA1.91
Balance Sheet
Debt/Equity0.01
Current Ratio11.68
Quick Ratio11.48
Book Value/Sh7.65 USD
Cash/Share5.53 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.7 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)24.13 USD
Upside (mean)+287.9%
Target Range18.00 USD – 30.00 USD
18.00+287.9% to mean30.00
# Analysts8
Ownership
Shares Out.36.29M
Float19.88M
Insiders3.15%
Institutions114.74%
Short Interest
Short Ratio4.7d
Short % Float11.73%
Short % Out.7.93%
Shares Short2.88M
Short (prev mo.)4.70M
Technical
SMA 5011.57 (-46.3%)
SMA 20018.90 (-67.1%)
Beta—
S&P 52W Chg15.78%
Avg Vol (30d)866.13K
Avg Vol (10d)980.36K
Technical Indicators
RSI (14)16.5
MACD-1.4509
MACD Signal-1.2979
MACD Hist.-0.1529
BB Upper11.41 USD
BB Middle8.681 USD
BB Lower5.957 USD
BB Width62.76%
ATR (14)0.6628 USD
Vol Ratio (20d)2.14x